(Q50585032)

16 March 2018

title

Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. (English)

1 reference

16 March 2018

1 reference

Beat Helbling

1

1 reference

16 March 2018

Ivan Stamenic

2

1 reference

16 March 2018

Francesco Viani

3

1 reference

16 March 2018

Jean-Jacques Gonvers

4

1 reference

16 March 2018

Jean-Francois Dufour

5

1 reference

16 March 2018

Jurg Reichen

6

1 reference

16 March 2018

Gieri Cathomas

7

1 reference

16 March 2018

Michael Steuerwald

8

1 reference

16 March 2018

Jan Borovicka

9

1 reference

16 March 2018

Markus Sagmeister

10

1 reference

16 March 2018

Eberhard L Renner

11

1 reference

16 March 2018

Investigators of the Swiss Association for the Study of the Liver

12

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 February 2002

1 reference

16 March 2018

published in

Hepatology

1 reference

16 March 2018

volume

35

1 reference

16 March 2018

issue

2

1 reference

16 March 2018

page(s)

447-454

1 reference

16 March 2018

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Prophylaxis and treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Inhibition of dengue virus replication by amantadine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Influenza virus. Amantadine blocks the channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Arenaviruses: inhibition by amantadine hydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Antiviral therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Recent advances in the molecular biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

Interferon plus amantadine versus interferon alone in the treatment of naı̈ve patients with chronic hepatitis C: a UK multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

The Roles of Vaccination and Amantadine Prophylaxis in Controlling an Outbreak of Influenza A (H3N2) in a Nursing Home

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31168

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.31168

1 reference

16 March 2018

1 reference

16 March 2018